1. Kendall RG. Erythropoietin. Clin Lab Haematol 2001; 23:71-80.

2. Erslev A. Humoral regulation of red cell production. Blood 1952; 8:349-357.

3. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252:5558-5564.

4. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl AcadSci USA 1985; 82:7580-7584.

5. Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem 1986; 261:3116-3121.

6. Syed RS, Reid SW, Li C, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998; 395:511-516.

7. Cheetham JC, Smith DM, Aoki KH, et al. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nature Struct Biol 1998; 5:861-866.

8. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. Mapping of the active site of recombinant human erythropoietin Blood 1997; 89:493-502.

9. Matthews DJ, Topping RS, Cass RT, Giebel LB. A sequential dimerization mechanism for erythropoietin receptor activation. Proceed Natl Acad Sci USA 1996; 93:9471-9476.

10. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the ery-thropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 1996; 35:1681-1691.

11. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993; 81:2223-2236.

12. Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986; 172:213-224.

13. Browne JKI, Cohen AM, Ergie JC, et al. Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 1986; 51:693-702.

14. Davis JM, Arakawa T, Strickland TW, Yphantis DA. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987; 26:2633-2638.

15. Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 1987; 262:12059-12076.

16. Takeuchi M, Kobata A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1991; 1:337-346.

17. Rush RS, Derby PL, Smith DM, et al. Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 1995; 67:1442-1452.

18. Delorme E, Lorenzini T, Giffin J, et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 1992; 31:9871-9876.

19. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84:3-10.

20. Jelkmann W. Use of recombinant human erythropoietin as an anti-anemic and performance enhancing drug. Curr Pharmaceut Biotech 2000; 1:11-31.

21. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72:449-489.

22. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228:1-14.

23. Spivak JL. The biology and clinical applications of recombinant erythropoietin. Semin Oncol 1998; 25(3 suppl 7):7-11.

24. Buemi M, Cavallaro E, Floccari F, et al. The pleiotropic effect of erythropoietin in the central nervous system. JNeuropathol Exp Neurol 2003; 62:228-236.

25. Spivak JL. Changing paradigms in anemia management. Adv Studies Med 2002; 22:610-619.

26. Roberts D, Smith DJ. Erythropoietin does not demonstrate circadian rhthym in healthy men. J Appl Physiol 1996; 80:847-851.

27. Pasqualetti P, Collacciani A, Casale R. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. Eur Rev Med Pharmacol Sci 2000; 4:111-115.

28. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14:22-28.

29. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271:17771-17778.

30. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20:5197-5206.

31. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107:43-54.

32. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-1340.

33. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464-468.

34. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxy-lase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002; 277:26351-26355.

35. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 2002; 367:3-5.

36. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59-67.

37. Koury MJ, Bondurant MC. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol 1988; 137:65-74.

38. Gregoli PA, Bondurant MC. The roles of Bcl-XL and apopain in the control of erythropoiesis by ery-thropoietin. Blood 1997; 89:630-640.

39. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22:503-514.

40. Sawyer T, Jacobs-Helber SM. Unraveling distinct intracellular signals that promote survival and proliferation: study of erythroproietin, stem cell factor, and constitutive signaling in leukemic cells. J Hematherapy Stem Cell Res 2000; 9:21-29.

41. Kashii Y, Uchida M, Kirito K, et al. A member of Forkhead family transcription factors FKHRL, is one of the downstream molecules of phosphatidylinositol 3-kinase-AKT activation pathway in ery-thropoietin signal transduction. Blood 2000: 96:941-949.

42. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, and Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 2003; 100:6523-6528.

43. Zamai L, Secchiero P, Pierpaoli S. et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000; 95:3716-3724.

44. Besarab A. Physiological and pharmacodynamic considerations for route of EPO administration. Semin Nephrol 2000; 20:364-374.

45. Soulliard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br J Clin Pharmacol 1996; 42:355-364.

46. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324:1339-1344.

47. Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 2002; 17:1621-1627.

48. Nissenson AR, Nimer SD, Wolcott DL. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med 1991; 114:402-416.

49. Adamson JW, Eschbach JW. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annnu Rev Med 1990; 41:349-360.

50. Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13 Suppl 2:23-27.

51. Kato A, Hishida A, Kumagai H, Furuya R, Nakajima T, Honda N. Erythropoietin production in patients with chronic renal failure. Ren Fail 1994; 16:645-651.

52. Ross RP, McCrea JB, Besarab A. Erythropoiein response to blood loss in hemodialysis patients is blunted but preserved. ASAIO J 1994; 40:M880-885.

53. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689-1692.

54. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001; 28:1-6.

55. Pedain C, Herrero J, Kunzel W. Serum erythropoietin levels in ovarian cancer patients receiving chemotherapy. Eur J Obstet Gynecol Reprod Biol 2001; 98:224-230.

56. Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nature Biotechnol 2003; 21:414-421.

57. Cotes PM, Bangham DR. Bio-assay of erythropoietin in mice made polycythemic by exposure to air at reduced pressure. Nature 1961; 191:1065-1067.

58. Allon M, Kleinman K, Walczyk M, Kaupke C, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002; 72:546-555.

59. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31:290-299.

60. Egrie JC, Cotes PM, Lane J, Gaines Das RE, Tam RC. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods 1987; 99:235-241.

61. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117-1124.

62 US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Guidance for industry: document for special controls for erythropoietin assay pre-market notifications [510(k)s]: issued April 28, 1999.

63. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Phar-mac 1992; 34:499-508.

64. Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61:393-398.

65. Flaharty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47:557-564.

66. Lasne F, deCeaurriz J. Recombinant erythropoietin in urine. Nature 2000; 405:635.

67. Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 2002; 48:2057-2059

68. Heatherington AC. Clinical pharmacokinetic properties of rHuEPO: a review. In: Molineux G, Foote MA, Elliot S, eds., Erythropoietins and Erythropoiesis: Molecular, Cellular, Preclinical, and Clinical Biology. Basel, Switzerland: Birkhausen 2003; pp. 87-112.

69. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76:1718-1722.

70. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995; 84:760-767.

71. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990a; 29:709-713.

72. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 1994; 5:177-185.

73. Boxenbaum H. Pharmacokinetic tricks and traps: flip-flop models. J Pharm Pharmaceut Sci 1998; 1:90-91.

74. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998; 64:412-423.

75. Markham A, Bryson HM. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drug Eval 1995; 49:232-254

76. Sans T, Joven J, Vilella E, Masdeu G, Farre M. Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusions. Clin Exp Pharmacol Physiol 2000; 27:179-184.

77. Hayashi T, Kinoshita H, Yukawa E, Higuchi S. Pharmacokinetic anaylysis of subcutaneous erythro-poietin administration with nonlinear mixed effect model including endogenous production. Br J Clin Pharmacol 1998; 46:11-19.

78. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Pharmacokinetics of epoetin in dialysis patients before and after correction of anaemia. Drug Invest 1994; 8:278-287.

79. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50:702-712.

80. Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW. Pharmacoki-netics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 21:635-642.

81. Kindler J, Eckardt KU, Ehmer B, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989; 4:345-349.

82. Neumayer HH, Brockmoller J, Fritschka E, Roots I, Scigalla P, Wattenberg M. Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis. Contrib Nephrol 1989; 76:131-141.

83. Hughes RT, Cotes PM, Oliver DO, et al. Correction of the anaemia of chronic renal failure with erythropoietin: Pharmacokinetics studies in patients on haemodialysis and CAPD. Contrib Nephrol 1989; 76:122-130.

84. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 1990; 66:83-86.

85. Egrie JC, Eschbach JW, McGuire T, Adamson JW. Pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered to hemodialysis (HD) patients. Kidney Int 1988; 33:abstract p. 262.

86. Lim V, DeGowin R, Zavala D, et al. Recombinant human erythropoietin treatment in predialysis patients: a double-blind placebo-controlled trial. Ann Intern Med 1989; 110:108-114.

87. Yamazaki C, Watanabe Y, Sakamoto N. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients. Nippon Jinzo Gakkai Shi 1993; 35:1233-1242.

88. Cotes JM, Pippard MJ, Reid CD, Winearls CG, Oliver DP, Royston JP. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoi-etin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 1989; 70:113-137.

89. Gladziwa U, Klotz U, Baumer K, Zollinger R, Mann H, Sieberth HG. Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration. Clin Pharmacokinet 1993; 25:145-153.

90. Hughes RT, Cotes PM, Oliver DO, et al. Correction of the anaemia of chronic renal failure with ery-thropoietin: Pharmacokinetic studies in patients on haemodialysis and CAPD. Contrib Nephrol 1989; 76:122-130.

91. Kampf D, Kahl A, Passlick J, et al. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Preliminary results. Contrib Nephrol 1989; 76:106-110.

92. Schouten JP, Voorhorst G, Helbing AR, Janssen JW, Diderich PP, Op de Hoek CT. Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment. Pharm WorldSci 1993; 15:252-256.

93. Petersen J, Kang MS, Hays MT. Erythropoietin can be administered during dialysis: a kinetic analysis. ASAIO J 1996; 42:27-33.

94. Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 1:425-427.

95. Boelaert JR, Schurgers ML, Matthys EG, et al. Comparative pharmacokinetics of recombinant ery-thropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous amulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989; 9:95-98.

96. Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59:399-402.

97. Bargman JM, Jones JE, Petro JM. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 1992; 12:369-372.

98. Taylor CA, Kosorok MR, Zimmerman SW, Johnson CA. Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique. Am J Kidney Dis 1999; 34:657-662.

99. Evans JH, Brockleank JT, Bowmer CJ, Ng PC. Pharmacokinetics of recombinant human erythropoietin in children with renal failure. Nephrol Dial Transplant 1991; 6:709-714.

100. Braun A, Ding R, Seidel C, Fies T, Kurtz A, Scharer K. Pharmacokinetics of recombinant human erythor-poietin applied subcutaneously to children with chronic renal failure. Pediatr Nephrol 1993; 7:61-64.

101. Cakar N. Ekim M, Tumer N, Yalcinkaya F, Akar N, Onaran HO. Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure. Int Urol Nephrol 1997; 29:377-383.

102. Montini G, Zacchello G, Perfumo F. Pharmacokinetics and pharmacodynamics of subcutaneous administration of r-HuEPO on CPD. A multicenter study from the Italian Registry of Pediatric CPD. J Am Soc Nephrol 1991; 2:283.

103. Kausz AT, Watkins SL, Hansen C, Godwin DA, Palmer RB, Brandt JR. Intraperitoneal erythropoietin in children on peritoneal dialysis: a study of pharmacokinetics and efficacy. Am J Kidney Dis 1999; 34:651-656.

104. Jensen JD, Jensen LW, Madsen JK, Poulsen L. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 1995; 54:111-116.

105. Franek E, Wiecek A, Kozielski J, et al. Half-time of erythropoietin in patients with chronic obstructive pulmonary diseases. Przegl Lek 1996; 53:592-594.

106. Bowen D, Ehmer B, Neubert P, Lewis T, Jacobs A. The clearance of a single iv bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol 1991; 19:613-616.

107. Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, Williams JD. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol 1991; 88:152-156.

108. Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 1994; 46:333-337.

109. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear phamacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997; 283:520-527

110. Macdougall IC. Once-weekly erythropoietic therapy: is there a difference between the available products? Nephrol Dial Transplant 2002; 17:2047-2051.

111. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal diease with recombinant human erythropoietin: result of a phase I and II clinical trial. N Engl J Med 1987; 316:73-78.

112. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57:411-418.

113. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. NEngl J Med 1998; 339:578-583.

114. Elliott S, Chang D, Delorme E, et al. Isolation and characterization of conformation sensitive antiery-thropoietin monoclonal antibodies: effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure. Blood 1996; 87:2714-2722.

115. Elliott S, Lorenzini T, Chang D, et al. Fine-structure epitope mapping of antierythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin structure. Blood 1996; 87:2702-2713.

116. Lis H, Sharon N. Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993; 218:1-27.

117. Endo Y, Nagai H, Watanabe Y, Ochi K, Takagi T. Heat-induced aggregation of recombinant erythro-poietin in the intact and deglycosylated states as monitored by gel permeation chromatography combined with a low-angle laser light scattering technique. J Biochem 1992; 112:700-706.

118. Coccia MA, Cooke K, Stoney G, et al. Novel erythropoiesis stimulating protein (darbepoetin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model. Exp Hematol 2001; 29:1201-1209.

119. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nepthrol 1999; 10:2392-2395.

120. Lerner G, Kale AS, Warady BA, et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 2002; 17:933-937.

121. Heatherington A, Schuller J, Dittrich C, the darbepoetin alfa 990146 Study Group, Mercer AJ, Rossi G. Intravenous (IV) administration of darbepoetin alfa to patients with nonmyeloid malignancies receiving multicycle chemotherapy; pharmacokinetic profiles. Proc ASCO 2002; 21:256b. Abstract 2844

122. Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC. Clinical trial simulation of a 200-|lg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Huntingt) 2002; 16:37-44.

123. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60:741-747.

124. Nissenson AR, Swan SK. Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40:110-118.

125. Smith R. Applications of darbepoietin-alpha, a novel erythropoiesis-stimulating protein, in oncology. Curr Opin Hematol 2002; 9:228-233.

126. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94:1211-1220.

127. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001; 84:17-23.

128. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87:268-276.

129. Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntington) 2002; 16:suppl 9.

130. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-475.

131. Sawada K, Krantz SB, Sawyer ST, Civin Ci. Quantitation of specific binding of eryathropoietin to human erythorid colony-forming cells. J Cell Physiol 1988; 137:337-345.

132. Sawyer ST, Hankins WD. The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis, and phosphorylation. Proc Natl Acad Sci USA 1993; 90:6849-6853.

133. Sawyer ST. Introduction: the erythropoietin receptor and signal transduction. Ann NY Acad Sci 1994; 718:185-190.

134. Fukuda M, Sasaki H, Fukuda MN. Structure and role of carbohydrate in human erythropoietin. Adv Exp Med Biol 1989; 271:53-67.

135. Watowich SS, Xie X, Klingmuller U, et al. Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. Blood 1999; 94:2530-2532.

136. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9:249-304.

137. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 1998; 68:1-18.

138. Goodson RJ, Katre NV. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 1990; 8:343-346.

139. He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of tri-chosanthin by site-directed pegylation. Life Sci 1999; 65:355-368.

140. Weich NS, Tullai J, Guido E, et al. Interleukin-3/erythropoietin fusion proteins: in vitro effectrs on hematopoietic cells. Exp Hematol 1993; 21:647-655.

141. Coscarella Carloni C, Liddi R, et al. Production of recombinant human GM-CSF-EPO hybrid proteins: in vitro biological characterization. Eur J Haematol 1987; 59:238-246.

142. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999; 274:24773-24778.

143. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 1998; 95:1184-1188.

144. Yi T, Zhang J, Miura O, Ihle JN. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood 1995; 85:87-95.

145. de la Chapelle A, Traskelin AL, Juvonen E. Truncated erythorpoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci USA 1993; 90:4495-4499.

146. Naffakh N, Henri A, Villeval JL, et al. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci USA 1995; 92:3194-3198.

147. Meyer F, Finer M. Gene therapy: progress and challenges. Cell Mol Biol 2001; 47:1277-1294.

148. Dalle B, Payen E, Regulier E, et al. Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts. Gene Ther 1999; 6:157-161.

149. Bohl D, Heard JM. Delivering erythropoietin through genetically engineered cells. J American Soc Nephrol 2000; 11:Suppl-62.

150. Payen E, Bettan M, Henri A, et al. Oxygen tension and a pharmacological switch in the regulation of transgene expression for gene therapy. J Gene Med 2001; 3:498-504.

151. Maruyama H, Higuchi N, Nishikawa Y, et al. Kidney-targeted naked DNA transfer by retrograde renal vein injection in rats. Hum Gene Ther 2002; 13:455-468.

152. Morlock M, Kissel T, Li YX, Koll H, Winter G. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in-vitro release properties. J Control Release 1998; 56:105-115.

153. Pistel KF, Bittner B, Koll H, Winter G, Kissel T. Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: influence of encapsulation technique and polyer composition on particle characteristics. J Control Release 1999; 59:309-325.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment